• +1-646-491-9876
    • +91-20-67278686

    Search

    Atherosclerosis Pipeline Review H1 2017

    Atherosclerosis Pipeline Review H1 2017

    • Report Code ID: RW0001799306
    • Category Pharmaceuticals
    • No. of Pages 225
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Atherosclerosis - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Atherosclerosis - Pipeline Review, H1 2017, provides an overview of the Atherosclerosis (Cardiovascular) pipeline landscape.

    Atherosclerosis (or arteriosclerotic vascular disease) is a condition where the arteries become narrowed and hardened due to an excessive build up of plaque around the artery wall. The disease disrupts the flow of blood around the body, posing serious cardiovascular complications. Symptoms of atherosclerosis are chest pain (angina) , pain in the leg, arm, and anywhere else that an artery is blocked, shortness of breath, fatigue, confusion (if the blockage affects circulation to the brain) and muscle weakness in the legs from lack of circulation.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Atherosclerosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Atherosclerosis (Cardiovascular) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Atherosclerosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atherosclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 5, 43 and 11 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 21 and 5 molecules, respectively.

    Atherosclerosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Atherosclerosis (Cardiovascular) .
    - The pipeline guide reviews pipeline therapeutics for Atherosclerosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Atherosclerosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Atherosclerosis (Cardiovascular) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Atherosclerosis (Cardiovascular)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Atherosclerosis (Cardiovascular) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Atherosclerosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    Introduction 5
    Atherosclerosis - Overview 6
    Atherosclerosis - Therapeutics Development 7
    Atherosclerosis - Therapeutics Assessment 21
    Atherosclerosis - Companies Involved in Therapeutics Development 33
    Atherosclerosis - Drug Profiles 51
    Atherosclerosis - Dormant Projects 192
    Atherosclerosis - Discontinued Products 199
    Atherosclerosis - Product Development Milestones 201
    Appendix 215

    List of Tables

    Number of Products under Development for Atherosclerosis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Atherosclerosis - Pipeline by AFFiRiS AG, H1 2017
    Atherosclerosis - Pipeline by Allergan Plc, H1 2017
    Atherosclerosis - Pipeline by Amgen Inc, H1 2017
    Atherosclerosis - Pipeline by Annexin Pharmaceuticals AB, H1 2017
    Atherosclerosis - Pipeline by Arisaph Pharmaceuticals Inc, H1 2017
    Atherosclerosis - Pipeline by Athera Biotechnologies AB, H1 2017
    Atherosclerosis - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Atherosclerosis - Pipeline by Cardax Inc, H1 2017
    Atherosclerosis - Pipeline by Cerenis Therapeutics Holding SA, H1 2017
    Atherosclerosis - Pipeline by ChemoCentryx Inc, H1 2017
    Atherosclerosis - Pipeline by CohBar Inc, H1 2017
    Atherosclerosis - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
    Atherosclerosis - Pipeline by DoNatur GmbH, H1 2017
    Atherosclerosis - Pipeline by Dybly AG, H1 2017
    Atherosclerosis - Pipeline by Esperion Therapeutics Inc, H1 2017
    Atherosclerosis - Pipeline by Forty Seven Inc, H1 2017
    Atherosclerosis - Pipeline by GenKyoTex SA, H1 2017
    Atherosclerosis - Pipeline by Immusoft Corp, H1 2017
    Atherosclerosis - Pipeline by Iproteos SL, H1 2017
    Atherosclerosis - Pipeline by Jenrin Discovery Inc, H1 2017
    Atherosclerosis - Pipeline by Kang Stem Biotech Co Ltd, H1 2017
    Atherosclerosis - Pipeline by KineMed Inc, H1 2017
    Atherosclerosis - Pipeline by Kowa Company Ltd, H1 2017
    Atherosclerosis - Pipeline by Lead Discovery Center GmbH, H1 2017
    Atherosclerosis - Pipeline by LipimetiX Development Inc, H1 2017
    Atherosclerosis - Pipeline by MedImmune LLC, H1 2017
    Atherosclerosis - Pipeline by Merck & Co Inc, H1 2017
    Atherosclerosis - Pipeline by Omeros Corp, H1 2017
    Atherosclerosis - Pipeline by Otsuka Holdings Co Ltd, H1 2017
    Atherosclerosis - Pipeline by Resverlogix Corp, H1 2017
    Atherosclerosis - Pipeline by Tolerys SA, H1 2017
    Atherosclerosis - Pipeline by Unity Biotechnology Inc, H1 2017
    Atherosclerosis - Pipeline by Vascular Biogenics Ltd, H1 2017
    Atherosclerosis - Pipeline by Vericel Corp, H1 2017
    Atherosclerosis - Pipeline by Vicore Pharma AB, H1 2017
    Atherosclerosis - Pipeline by XBiotech Inc, H1 2017
    Atherosclerosis - Dormant Projects, H1 2017
    Atherosclerosis - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Atherosclerosis - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Atherosclerosis - Dormant Projects, H1 2017 (Contd..3) , H1 2017
    Atherosclerosis - Dormant Projects, H1 2017 (Contd..4) , H1 2017
    Atherosclerosis - Dormant Projects, H1 2017 (Contd..5) , H1 2017
    Atherosclerosis - Dormant Projects, H1 2017 (Contd..6) , H1 2017
    Atherosclerosis - Discontinued Products, H1 2017
    Atherosclerosis - Discontinued Products, H1 2017 (Contd..1) , H1 2017

    List of Figures

    Number of Products under Development for Atherosclerosis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    AFFiRiS AG
    Allergan Plc
    Amgen Inc
    Annexin Pharmaceuticals AB
    Arisaph Pharmaceuticals Inc
    Athera Biotechnologies AB
    Bristol-Myers Squibb Company
    Cardax Inc
    Cerenis Therapeutics Holding SA
    ChemoCentryx Inc
    CohBar Inc
    Daiichi Sankyo Company Ltd
    DoNatur GmbH
    Dybly AG
    Esperion Therapeutics Inc
    Forty Seven Inc
    GenKyoTex SA
    Immusoft Corp
    Iproteos SL
    Jenrin Discovery Inc
    Kang Stem Biotech Co Ltd
    KineMed Inc
    Kowa Company Ltd
    Lead Discovery Center GmbH
    LipimetiX Development Inc
    MedImmune LLC
    Merck & Co Inc
    Omeros Corp
    Otsuka Holdings Co Ltd
    Resverlogix Corp
    Tolerys SA
    Unity Biotechnology Inc
    Vascular Biogenics Ltd
    Vericel Corp
    Vicore Pharma AB
    XBiotech Inc

    Request for Sample

    Report Url http://www.reportsweb.com//atherosclerosis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//atherosclerosis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//atherosclerosis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments